dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Muntañola, Ana |
dc.contributor.author | Arguiñano-Pérez, José María |
dc.contributor.author | Davila Valls, Julio |
dc.contributor.author | Gonzalez de Villambrosia, Sonia |
dc.contributor.author | Cecilia del Carmen, Carpio Segura |
dc.contributor.author | Jimenez-Ubieto, Ana |
dc.date.accessioned | 2023-05-12T11:24:04Z |
dc.date.available | 2023-05-12T11:24:04Z |
dc.date.issued | 2023-02 |
dc.identifier.citation | Muntañola A, Arguiñano‐Pérez JM, Dávila J, González de Villambrosia S, Carpio C, Jiménez‐Ubieto A, et al. Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting. Clin Transl Sci. 2023 Feb;16(2):305–12. |
dc.identifier.issn | 1752-8062 |
dc.identifier.uri | https://hdl.handle.net/11351/9524 |
dc.description | Seguretat; Trastorns limfoproliferatius de cèl·lules B; Entorn real |
dc.description.sponsorship | This study was funded by Sandoz Group, a Novartis Division, as an investigator project in the GELTAMO group. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Clinical and Translational Science;16(2) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Leucèmia limfocítica crònica - Tractament |
dc.subject | Trastorns limfoproliferatius - Tractament |
dc.subject | Medicaments biològics - Efectes secundaris |
dc.subject.mesh | Leukemia, Lymphocytic, Chronic, B-Cell |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Biosimilar Pharmaceuticals |
dc.subject.mesh | /adverse effects |
dc.title | Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1111/cts.13450 |
dc.subject.decs | leucemia linfocítica crónica de células B |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | fármacos biosimilares |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.1111/cts.13450 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Muntañola A] Department of Hematology, Hospital Universitari Mutua Terrassa, Terrassa, Spain. [Arguiñano-Pérez JM] Department of Hematology, Hospital Universitario de Navarra, Pamplona, Spain. [Dávila J] Department of Hematology, Complejo Asistencial de Ávila, Ávila, Spain. [de Villambrosia SG] Department of Hematology, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain. [Carpio C] Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Jiménez-Ubieto A] Department of Hematology, Hospital 12 de Octubre, Madrid, Spain |
dc.identifier.pmid | 36385738 |
dc.identifier.wos | 000890135800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |